Coming off Wegovy: what to expect

The short answer

Semaglutide (Wegovy) has a half-life of approximately seven days. Drug levels fall gradually over four to five weeks after the last injection — not overnight. Most people feel little in week one. By weeks three to six, appetite typically returns. By week eight, you are largely without the pharmacological buffer. The number on the scale is a lagging indicator. Hunger and food noise shift before weight does, so monitoring only weight means missing the earliest warning.

What the STEP 1 withdrawal data actually show

The STEP 1 trial extension followed participants who had lost around 17% of body weight on semaglutide. One year after stopping, they had regained approximately two-thirds of that loss. Blood pressure, HbA1c and lipids tracked back toward baseline in parallel. [1] The regain was not a discipline failure — it was a predictable pharmacological withdrawal. The 2026 BMJ systematic review of 37 studies estimated mean regain of roughly 0.4 kg per month after stopping obesity medication. For higher-potency agents, the rate was modelled as faster. [2]

Weeks 1–2: the deceptive quiet window

Gastric emptying begins normalising and meals may feel slightly less filling, but central appetite suppression persists while drug levels remain meaningful. Most people feel broadly fine. This is the period in which people assume they are safe and stop monitoring — and that is precisely when to start. Weigh daily and track the trend, not individual readings. Anchor breakfast around 30–40 g of protein. Do not reduce resistance training.

Weeks 3–6: appetite and food noise return

By week three semaglutide is approaching low levels; by week six it is largely cleared. Food noise — the background pull toward eating the drug was suppressing — typically returns in this window. Evening hunger often arrives first. Alcohol interest may return if it had been blunted. Portion sizes begin drifting without feeling like a decision. Tighten meal structure now, not after weight has moved. If you are on antihypertensives, check your blood pressure — weight loss may have made the dose excessive, and the reverse transition needs watching too. [3] If you have type 2 diabetes, a glucose monitoring plan should already be in place with your clinician.

Beyond 6 weeks: the maintenance question

After week six you are in maintenance without pharmacological support. Consistent resistance training is more protective than any specific dietary approach at this stage — not because it burns calories, but because lean mass preserves metabolic rate as weight fluctuates. If weight trends upward by more than 3–5% from your exit point, that warrants a clinical conversation. Restarting is a legitimate clinical option. NICE guidance on obesity medicine acknowledges ongoing treatment may be appropriate long-term for some patients. [4]

Blood pressure: the aspect most guides ignore

Meaningful weight loss — 10–15% of body weight — frequently reduces blood pressure enough to make antihypertensive medication relatively excessive. Stopping Wegovy changes the trajectory again. The timing is unpredictable. If you are on antihypertensives, check blood pressure at weeks two, four, and six after stopping. If dizziness or postural symptoms appear, involve your GP before that schedule. [3]

If you have type 2 diabetes

Wegovy is licensed for weight management, but semaglutide's GLP-1 mechanism does lower glucose. Stopping will affect glycaemic control to some degree even if Wegovy was not your primary diabetes medication. Agree a monitoring plan before stopping. If you are on sulphonylureas or insulin alongside Wegovy, hypoglycaemia risk changes when the drug clears. [5]

When to seek urgent help

Severe persistent abdominal pain — particularly radiating to the back, or with vomiting — requires urgent assessment. The MHRA strengthened pancreatitis warnings for GLP-1 agents in 2026; symptoms can occur after stopping as well as during treatment. [6] Also seek urgent help for severe hypoglycaemia symptoms if on insulin or sulphonylureas, or for persistent vomiting with dehydration.